AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Kamada Ltd.

Registration Form Jul 20, 2017

6874_rns_2017-07-20_a40aeee5-314c-4a50-9dbe-b63ca2343657.htm

Registration Form

Open in Viewer

Opens in native device viewer

_________ false

����� ��"� 2 380
KAMADA LTD
Corporation no: 511524605 10991
- - -
Israel Securities Authority Tel Aviv Stock Exchange C002 ( Public ) Reported via MAGNA: 20/07/2017
www.isa.gov.il www.tase.co.il Reference: 2017-02-062635 Time of broadcast: 13:53 13:50:38

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onKamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

200717_Final_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: TASE Date of revision of form structure: 16/07/2017
Address: Holtzman 2 4081 , Rehovot 7670402   ISRAEL , Tel: 08-9406472 , Fax: 08-9406473
E-mail address: [email protected]   Company site: www.kamada.com
Previous names of reporting entity:
Name of the Signatory: Fhima Lior Position of Signatory in the reporting corporation: Director of Finance Name of Employer Company:
Address: Sapir 7 , Ness Ziona 7403630 Telephone: 08-9913168 Facsimile: 08-9912083 E-mail: [email protected] 2

Talk to a Data Expert

Have a question? We'll get back to you promptly.